Estrella Immunopharma Inc. (ESLA)
ESLA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ESLA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001844417 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result, management has determined that there is a substantial doubt about its ability to continue as a going concern." | 10-Q 2026-08-13 |
| Cash and burn | $100K cash; operating cash flow -$2.3M a quarter. | Report 2026-06-30 |
| Shares outstanding | 43,497,864 (2026-08-11); 37,065,589 a year earlier; 2,168,354 three years earlier. | Cover page 2026-08-11 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-01-06 |
| Exchange deficiency notices, 12 months | 3 (8-K item 3.01) | 8-K 2026-09-08 |
| Auditor | Macias Gini & O'Connell LLP, Irvine, California, United States | PCAOB Form AP 2026-03-23 |
| Late filings, 12 months | 1 NT notice | NT 10-Q 2026-05-18 |
| Insider trades, 12 months | Bought $1K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$2.3M | -$1.8M | $100K | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$2.3M | -$6.7M | $1.9M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2025 2025-12-31 | Not filed | -$613K | -$177K | $1.4M | No debt tags | Needs four quarters | 10-K 2026-03-18 |
| Q3 2025 2025-09-30 | Not filed | -$4.8M | -$727K | $1.6M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$5.5M | -$415K | $1.3M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$2.1M | -$466K | $421K | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2024 2024-12-31 | Not filed | -$1.1M | -$896K | $917K | No debt tags | Needs four quarters | 10-K 2026-03-18 |
| Q3 2024 2024-09-30 | Not filed | -$3.4M | -$2.2M | $1.8M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B3 | 2026-02-13 |
| Latest annual report AMENDMENT NO. 1 TO FORM 10-K | 10-K/A | 2026-04-30 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-16 |
| Latest current report CURRENT REPORT | 8-K | 2026-10-29 |
| Latest proxy | DEF 14A | 2026-05-27 |
Source: SEC EDGAR submissions feed, 260 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +37.1% |
| 1 month | +63.7% |
| 3 months | -29.1% |
| Year to date | -67.1% |
| 1 year | -76.6% |
| From 52-week high | -77.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| ESLAW | Estrella Immunopharma Inc. Warrant | $0.0878 |
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ABOS | Acumen Pharmaceuticals Inc. | $0.2160 | +0.93% | $15.6M |
| PLUR | Pluri Inc. | $1.04 | -0.95% | $15.0M |
| BSEM | BioStem Technologies Inc. | $0.9601 | -8.56% | $18.4M |
| ATYR | aTyr Pharma Inc. | $5.24 | -14.17% | $13.4M |
| PASG | Passage Bio Inc. | $4.13 | -2.82% | $13.3M |
| JSPR | Jasper Therapeutics Inc. | $11.77 | -13.96% | $13.1M |
| DYAI | Dyadic International Inc. | $0.3200 | -2.14% | $12.8M |
| BCDA | BioCardia Inc. | $0.7901 | -4.92% | $12.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier